Since 2012, more than 73,000 schools have enrolled in the EpiPen4Schools^® program, and results from surveys of participating schools demonstrate the need to continue to engage all schools. According to the most recently published data from our EpiPen4Schools survey, there were more than 2,000 anaphylactic events in 2014/2015, as reported by more than 12,000 schools participating in the program, and of the events where epinephrine was administered, half were treated with an epinephrine auto-injector provided by the program. Food was the most common trigger, though in 33% of events, the trigger was unknown.  Nearly 25% of these occurred in individuals with no previously known allergies.

For students and other individuals with known severe allergies, they must always take care to avoid their allergens and have access to epinephrine, the only first-line treatment for anaphylaxis, should exposure occur. There are several epinephrine choices now available on the market. If your constituents have a prescription for EpiPen^® or EpiPen Jr^® Auto-Injectors, please help ensure they are familiar with the patient resources Mylan offers.

Mylan’s Epinephrine Auto-Injector Patient Resources

·         Includes information about the authorized generic for EpiPen Auto-Injector; the savings cards available for both EpiPen Auto-Injector and the authorized generic; Mylan’s patient assistance program and the EpiPen4Schools program.

 EpiPen4Schools Infographic and EpiPen4Schools Fact Sheet

·         Provides more detail about the EpiPen4Schools program, including participation statistics, survey results and myths and facts.

Additional information